Profile for Denmark Patent: 1482932

US Patent Family Members and Approved Drugs for Denmark Patent: 1482932

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
7,425,637	Mar 13, 2026	Astrazeneca	KOSELUGO	selumetinib sulfate
7,777,050	Mar 13, 2026	Array Biopharma Inc	MEKTOVI	binimetinib
8,178,693	Mar 13, 2026	Astrazeneca	KOSELUGO	selumetinib sulfate

Detailed Analysis of the Scope, Claims, and Patent Landscape for Denmark Patent DK1482932

---

Introduction

Denmark Patent DK1482932 pertains to an inventive pharmaceutical patent granted to a specific formulation, compound, or method relevant to the development and commercialization of therapeutic agents. A comprehensive understanding of its scope, claims, and the surrounding patent landscape assists stakeholders—including pharmaceutical companies, patent attorneys, and R&D entities—in assessing patent strength, potential freedom-to-operate (FTO), and future innovation directions.

This analysis dissects the patent’s claims, evaluates its coverage, and contextualizes it within the broader patent landscape. The insights aim to inform strategic decision-making pertinent to licensing, research, or competitive intelligence.

---

Patent Overview

Patent Number: DK1482932
Grant Date: Not specified here (assuming recent or relevant to current pharmaceutical innovations)
Applicant/Owner: Typically pharmaceutical entities or academia, but specifics require the patent document.
Field of Technology: Likely pertains to a pharmaceutical compound, formulation, or method, given the context.

The document’s abstract, claims, and detailed description shape its legal and commercial scope, thus demanding focused scrutiny.

---

Scope and Claims Analysis

Scope of the Patent

The scope of DK1482932 is primarily encapsulated within its claims, defining the legal boundaries of protected innovations. Generally, pharmaceutical patents include claims covering:

• Novel compounds or chemical entities
• Specific pharmaceutical formulations or compositions
• Methods of manufacturing or use
• Biomarkers or diagnostic methods associated with the compound

In this case, the scope appears centered on a new pharmaceutical compound or a specific formulation with potential therapeutic application, possibly a novel chemical entity or a specific dosage form.

---

Claims Analysis

1. Independent Claims
These serve as the broadest protective elements, setting the primary boundaries of patent coverage.

• Chemical Structure Claims: Likely claim the chemical formula or structure of a novel compound, possibly defining the molecule's core scaffold with specific substituents.
• Method of Use: Claims may specify the therapeutic methods, such as treatment of particular diseases or conditions.
• Pharmaceutical Composition: Claims could delineate the combination of the compound with excipients or carriers, defining a unique formulation.

2. Dependent Claims
Dependent claims narrow the scope through specific features, such as:

• Specific chemical substitutions
• Particular dosage forms or delivery mechanisms
• Use in specific patient populations or disease states

3. Claim Language and Interpretation

Last updated: July 29, 2025

The legal strength hinges on claim clarity, breadth, and support in the description. Phrases such as "comprising," "consisting of," or "wherein" influence the scope:

• "Comprising" indicates open claims, covering compositions that include the specified elements plus others.
• "Consisting of" or "consisting essentially of" restrict claims, conferring narrower protection.

If the independent claims are broad, they might cover substantial classes of compounds or methods, but potential for invalidation exists if prior art predates the patent.

---

Patent Landscape Context

Prior Art and Novelty Considerations

The patent landscape surrounding DK1482932 involves assessing:

• Existing Pharmaceuticals: Patents or publications similar in chemical structure or therapeutic application.
• Patent Filings in Similar Indications: Overlapping claims in related drug classes or chemical scaffolds.
• Global Patent Families: Similar patents filed internationally to protect the same invention.

In Denmark and broader jurisdictions (EPO filings, PCT applications), the novelty or inventive step could be challenged if prior art exists that discloses similar compounds or methods.

Competitors and Patent Filing Strategies

Major pharmaceutical entities operating in Denmark and Europe likely hold patents in related classes, creating a dense patent landscape. Strategies may include:

• Filing related patents with narrow claims to protect incremental improvements
• Attaining patent term extensions or supplementary protection certificates (SPCs)
• Conducting freedom-to-operate analyses considering overlapping patents

Legal and Regulatory Considerations

European patent law emphasizes inventive step and industrial applicability. The scope of DK1482932, assuming it successfully claims a novel, non-obvious compound or method, stands to be robust but could face validity challenges if prior art is strong.

---

Implications for Stakeholders

• Pharmaceutical Innovators: DK1482932 may block competitors from developing similar drugs within Denmark; validating the scope helps prevent infringement.
• Patent Holders: Strategic enforcement or licensing; assessing scope for carve-outs or licensing deals.
• Research Entities: Need to evaluate potential infringement risks when conducting related research in Denmark or the European Union.

---

Conclusion

DK1482932 appears to cover a specific pharmaceutical compound or formulation with claims likely centered on chemical structure and therapeutic use. Its legal and commercial value depends on the breadth of the claims and the surrounding patent landscape. Close monitoring of prior art and related patents remains essential for stakeholders planning development or commercialization strategies.

---

Key Takeaways

• The scope of DK1482932 hinges on the breadth of its independent claims, especially chemical and use claims.
• Robust claims that cover a broad chemical class but are supported by detailed descriptions provide strong legal protection.
• A dense patent landscape in the pharmaceutical area underscores the importance of conducting comprehensive freedom-to-operate and invalidity analyses.
• Stakeholders should evaluate the patent’s claims relative to existing patents to identify potential licensing opportunities or infringement risks.
• Strategic patent prosecution and enforcement can optimize commercial advantage within Denmark and broader European markets.

---

FAQs

Q1: How do I determine whether DK1482932 covers a chemical compound or a method of treatment?
A1: Review the independent claims—if they specify chemical structures, it focuses on compounds; if they describe procedures or uses, then it pertains to methods of treatment.

Q2: Can the scope of DK1482932 be broadened or limited through legal challenges?
A2: Yes, through patent opposition or validity proceedings, claims can be challenged for lack of novelty or inventive step, potentially leading to narrowing or invalidation.

Q3: How does DK1482932 compare to international patents filed for similar compounds?
A3: Cross-jurisdictional comparison involves examining patent families, similar claims, and priority dates to assess overlaps and potential FTO issues.

Q4: What strategies can be employed if a competitor holds a patent similar to DK1482932?
A4: Options include licensing negotiations, designing around the patent, or pursuing invalidity if prior art challenges exist.

Q5: Are there specific considerations for enforcing DK1482932 within Denmark?
A5: Enforcement entails demonstrating infringement, often requiring detailed claim interpretation and potentially, a court’s technical assessment of the accused product or process.

---

References

1. Official DK1482932 patent document (assumed)
2. European Patent Office (EPO) patent databases
3. Patent law and practice guidelines (EPC Rules, Denmark Patent Law)
4. Patent landscape reports relevant to pharmaceutical compounds